These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study. Milano C; Turco F; Pizzanelli C; Bonanni E; Siciliano G; Fornai F; Giorgi FS Epilepsy Behav; 2021 Feb; 115():107706. PubMed ID: 33423017 [TBL] [Abstract][Full Text] [Related]
3. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623 [TBL] [Abstract][Full Text] [Related]
5. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020. Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential. Serafini A; Gerard E; Genton P; Crespel A; Gelisse P CNS Drugs; 2019 Mar; 33(3):195-208. PubMed ID: 30747367 [TBL] [Abstract][Full Text] [Related]
7. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy. Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy. Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184 [TBL] [Abstract][Full Text] [Related]
9. [Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate]. Crespel A; Velizarova R; Genton P; Gélisse P Therapie; 2009; 64(5):321-3. PubMed ID: 19863907 [TBL] [Abstract][Full Text] [Related]
10. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE; Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757 [TBL] [Abstract][Full Text] [Related]
11. Patterns and prognostic markers for treatment response in generalized epilepsies. Gesche J; Hjalgrim H; Rubboli G; Beier CP Neurology; 2020 Nov; 95(18):e2519-e2528. PubMed ID: 32817177 [TBL] [Abstract][Full Text] [Related]
12. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center. Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road. Baheti N; Rathore C; Bansal AR; Shah S; Veedu HK; Prakash S; Kanhere K; Jaiswal SK; Jukkarwala A; Murthy JMK; Radhakrishnan K Seizure; 2021 Nov; 92():112-117. PubMed ID: 34496330 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial. Machado RA; García VF; Astencio AG; Cuartas VB Seizure; 2013 Dec; 22(10):846-55. PubMed ID: 23916525 [TBL] [Abstract][Full Text] [Related]
15. Reconsidering the role of selective sodium channel blockers in genetic generalized epilepsy. Cerulli Irelli E; Morano A; Fanella M; Orlando B; Salamone EM; Giallonardo AT; Di Bonaventura C Acta Neurol Scand; 2021 Dec; 144(6):647-654. PubMed ID: 34314016 [TBL] [Abstract][Full Text] [Related]
16. Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy. Komatsubara T; Kobayashi Y; Hiraiwa A; Magara S; Hojo M; Ono T; Okazaki K; Fukuda M; Tohyama J Epilepsia Open; 2022 Jun; 7(2):332-343. PubMed ID: 35445562 [TBL] [Abstract][Full Text] [Related]
19. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Montouris G; Abou-Khalil B Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy. Ascoli M; Mastroianni G; Gasparini S; Striano P; Cianci V; Neri S; Bova V; Mammì A; Gambardella A; Labate A; Aguglia U; Ferlazzo E Expert Rev Neurother; 2021 Nov; 21(11):1265-1273. PubMed ID: 33993822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]